OncoMatch/Clinical Trials/NCT07309289
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
Is NCT07309289 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including NALIRIFOX plus targeted therapy and FOLFOX plus targeted therapy for metastatic colorectal cancer (crc).
Treatment: NALIRIFOX plus targeted therapy · FOLFOX plus targeted therapy — To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IV
Metastatic disease required
inoperable metastatic colorectal adenocarcinoma; The unresectable stage of metastatic disease has not received any systemic antitumor therapy; The presence of at least 1 measurable lesion that can be evaluated according to the RECIST v1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: irinotecan
Received irinotecan before enrollment
Lab requirements
Blood counts
Normal bone marrow function
Kidney function
Normal organ function
Liver function
Normal organ function
Normal bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify